Series A extension · Biotech
Alchemab receives £25m from British Business Bank
The Series A extension supports protective-antibody research and clinical programmes.
British Business Bank announced a £25 million investment in Alchemab Therapeutics on July 9, 2026, as part of its Series A extension. The transaction brought total Series A investment to £109 million.
The UK biotechnology company will expand research and its antibody database, while advancing two wholly owned programmes towards clinical development. It identifies protective antibodies in people who show resilience to disease.
Use of funds
Expand research and the protective-antibody database
Advance two wholly owned programmes into clinical development
Funding history
Series A extension · This round£25M
Parkinson research grant$595KBiomedical Catalyst grant£1.7MSeries A£60MBiomedical Catalyst grantUndisclosed